▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Amar Khatri

XMFepsrevanalyst

Recent Articles by Amar Khatri

GettyImages-849193388

Jul 25, 2020 by Amar Khatri

Is CRISPR Therapeutics Stock a Buy?

The gene-editing pioneer is a favorite among biotech investors and its stock is hitting new highs.

GettyImages-1142558430

Jul 14, 2020 by Amar Khatri

2 Top Cancer Treatment Stocks To Watch In July

These hidden gems have the potential to deliver significant returns to their shareholders over the long run.

getty-woman-looking-pills-2

Jul 6, 2020 by Amar Khatri

These 2 Pharma Stocks Could Be Top Stocks in 2020

These pharma stocks are undervalued, and could be solid picks over the long term.

GettyImages-1151193052

Jul 5, 2020 by Amar Khatri

Is Dynavax Technologies Stock a Buy?

This stock has the potential to break new highs with its key hepatitis B vaccine and emerging vaccine-adjuvant platform for COVID-19 vaccines.

GettyImages-1168199832

Jul 1, 2020 by Amar Khatri

2 Biotech Stocks That Could Soar in 2020

These companies offer promising pipelines that could deliver in the long term.

GettyImages-484278592

Jun 24, 2020 by Amar Khatri

Better Buy: Illumina vs. Guardant Health

Which stock wins in a matchup between these two healthcare stocks?

GettyImages-1151402031

Jun 16, 2020 by Amar Khatri

2 Top Cancer Treatment Stocks to Buy in June

If you have cash to spare, these cancer stocks are set to soar.

GettyImages-1006455620

Jun 10, 2020 by Amar Khatri

3 Drug Stocks That Could Soar in 2020

Have extra cash to spare? These drug stocks are significantly undervalued and could make you wealthy in the long run.

GettyImages-466481854

Jun 9, 2020 by Amar Khatri

Is Aurinia Pharmaceuticals Stock a Buy?

This biopharma’s drug could be a home run for investors.

GettyImages-663006630

Jun 3, 2020 by Amar Khatri

Better Buy: CRISPR Therapeutics vs. Intellia

Which gene editing stock wins this matchup?

GettyImages-1139090560

Jun 2, 2020 by Amar Khatri

Is Acadia Pharmaceuticals a Buy?

A strong Q1 performance set the tone, but commitment to its strategy will be key to drive the stock higher.

GettyImages-1134075979

May 19, 2020 by Amar Khatri

Is Amarin Stock a Buy?

Record revenues, international growth, and a potential legal strategy may provide upside.

DNA sequence genetics test genomics

May 12, 2020 by Amar Khatri

Is Exact Sciences Stock a Buy?

Q1 results were mixed, but the company’s strategy may be key for top-line growth ahead.

pillspillspills

Apr 29, 2020 by Amar Khatri

Is Catalyst Pharmaceuticals a Buy?

Several catalysts could drive this biopharma higher, but there are some significant risks ahead, too.

Blue poker chips on stock market background

Apr 23, 2020 by Amar Khatri

Your 2 Top Profit Opportunities in 2020

These two underrated biotech stocks have the potential to soar.

financial health stethoscope money cash hundred bills medical healthcare

Apr 16, 2020 by Amar Khatri

Is Exelixis a Buy?

Cheap and ready to outperform, this under-the-radar biotech stock could be a winner.

red blood cells abstract

Apr 8, 2020 by Amar Khatri

Is BioMarin Pharmaceutical Stock a Buy?

Is this a prime opportunity for investors to buy the gene therapy drugmaker?

bottles of prescription medicine sitting on shelves in cabinet drugs pills

Mar 12, 2020 by Amar Khatri

This 1 Stock Is a Good Buy During the Coronavirus Sell-Off

Acadia Pharmaceuticals' track record of success and strong pipeline offers an attractive long-term opportunity for investors, especially at a depressed price.

hypodermic needles syringe drug pharma

Mar 2, 2020 by Amar Khatri

Can Halozyme Therapeutics Continue Its Momentum in 2020?

The biopharma's strategic moves in 2019 may set the company up for long term growth.

research scientists drugs pharma biotech

Mar 2, 2020 by Amar Khatri

Here's Why Clovis Oncology Has Upside Potential in 2020

The cancer-drug maker has a novel medicine that may provide growth opportunities in other areas of cancer.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services